Home Pharma China Web Edition Pharma China Archives Online Databases Subscription/Order/Info Event Calendar China Pharma Providers About Us
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Featured News
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor´s Picks
 
 
 
China Healthcare Faces Major Overhaul As Chinese Leadership Sets New Course
Chief Editor James Shen offers his regular monthly review of the Chinese healthcare sector with this issue's emphasis on President Xi's new healthcare vision as well as a... (8/30/2016)
   
IPEC China Joins EXCiPACT, Promoting Excipient Safety, Quality (9/27/2016)
China Fast Tracks Merck's Cancer Drug For Approval, But There's A Catch (9/27/2016)
Aussie Entrepreneurs' Biotech Co Gets Demolished in China by Local Mayor Dubbed 'Demolition Geng' (9/26/2016)
Hard to Swallow: Emerging Markets Get Tougher for Drugmakers (9/23/2016)
Revised Draft Cyber Security Law May Significantly Impact Multinationals in China (9/16/2016)
ICH and PIC/S: No Expectations for China to Join Despite Ongoing Talks with CFDA (9/13/2016)
The BATtle in Chinese Internet Healthcare Market (9/12/2016)
Quick Thoughts on Tele-Health in China (9/8/2016)
Kobayashi Pharma: China Business Growth without China Presence (9/7/2016)
What's Influencing Digital Health Growth in China? (9/6/2016)
Ramping Up of Antitrust Enforcement in the Chinese Pharmaceutical Sector (9/5/2016)
Why Chinese Drugmakers Are Looking Overseas (8/31/2016)
KPMG's New Report: Life Sciences in China: The CEO's Perspective (8/30/2016)
China Healthcare Faces Major Overhaul As Chinese Leadership Sets New Course (8/30/2016)
China to Grow Big on e-Healthcare Data (8/25/2016)
Recent Executive Movements  (9/29/2016)
NHFPC Suggests Full BMI Coverage of Esse...  (9/28/2016)
Bayer Troubled by Integration of Acquire...  (9/28/2016)
CFDA Issues Policy for Tracing of Food a...  (9/28/2016)
New Reports: Chinese Pharma Distribution...  (9/28/2016)
2016 Ranking of Top Chinese Pharma Compa...  (9/28/2016)
Global API Market to Reach US$186 Bn by ...  (9/27/2016)
Global API Market to be worth $219.60 Bi...  (9/27/2016)
Histogen and Huapont Life Sciences Affil...  (9/27/2016) (free)
Chinese NGO Introduces "Reference List o...  (9/27/2016)
MicuRx Raises $55M for Phase III Antibio...  (9/26/2016)
Updated: Merck Finds Shortcut for Antica...  (9/26/2016)
WuXi Biologics Opens Perfusion Biologics...  (9/23/2016)
Recent Executive Moves  (9/22/2016)
28 Central Government Agencies Sign MOU ...  (9/22/2016)
Top Three TCs Account for 68% of Overall Global Pharma I...
Sanofi, Boehringer Ingelheim Agree to Swap Business Asse...
Novartis Splits Pharmaceuticals Division Into Two Busine...
IMS Health Holdings and Quintiles to Combine
Pfizer Abandons Plans to Take Over Allergan Citing New U...
IMS: Chinese Retail Pharmacy Sales Up 6.3% in MAT Q2/2016
IMS: Chinese Hospital Drug Sales Up 6.2% in Q2/2016
Nicholas Hall Reports MAT Q1/2016 Data on the Chinese OTC Analg...
IMS: Chinese OTC Drug Market Up 6.0% in 2015
Sinohealth: Chinese Pharma Growth Expected to Slow Further in 2...
Bayer Troubled by Integration of Acquired OTC Business in Ch...
New Reports: Chinese Pharma Distribution Sustains Double Dig...
2016 Ranking of Top Chinese Pharma Companies by R&D ...
Histogen and Huapont Life Sciences Affiliate to Co-develop H...
MicuRx Raises $55M for Phase III Antibiotic Trials
CFDA Issues Policy for Tracing of Food and Drug Products...
28 Central Government Agencies Sign MOU for Joint Punish...
CFDA Solicits Public Comments on Draft Rules on Imported...
CFDA Seeks Comments on New Review Guideline for Equivale...
CFDA Releases New Announcement for Excessively-Supplied ...
US Court Threw Out China Vitamin C Price Fixing Decision
AstraZeneca to Pay Over $5M to Settle with USSEC for Alleged...
BMS Board Directors Sued by Investor for Failing to Address ...
The SPP Issues Notice for Occupational Crimes in Food and Dr...
NDRC Fines Three Domestic Pharma Cos CNY 2.6M for Price Mono...
Global API Market to Reach US$186 Bn by 2020: PMR
Global API Market to be worth $219.60 Billion by 2023: T...
USFDA Warns Xinxiang Tuoxin Biochemical for cGMP Deviati...
Frontage, Zhejiang Jiuzhou Form CDMO JV for NCE and API ...
Chinese API Industry Revenue Expected to Grow at 9.5% GA...
BeiGene Granted CFDA Approval for Clinical Trial of Anti...
Nobel Laureate Tu Youyou's Team Reports New Progress on ...
BeiGene Approved for Clinical Trials in China with PARP ...
CFDA Accepts Eisai's NDA for Anticancer Halaven
Immunicum to be Granted Chinese Patent for Anticancer CD...
NHFPC Suggests Full BMI Coverage of Essential Drugs at N...
Chinese NGO Introduces "Reference List of Chinese Orphan...
NDRC Official Lays Out Directions of Medical Service Pri...
NHFPC and MOF Issue Notice to Advance Overall Reform of ...
Lung Cancer Most Common Cancer in China: Air Pollution T...
Recent Executive Movements
Recent Executive Moves
Recent Executive Movements
Recent Executive Moves
Recent Executive Moves
Upcoming Event: Pharma Business Development Course
Upcoming Event: Pharma Business Development Course
Upcoming Event: Pharma 2016: Sales & Marketing Excel...
Upcoming Event: Pharma Business Development Course
Upcoming Event: Pharma Congress 2016
Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...
WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...
  WiCON Officially Publishes Chi...
  WiCON and PharmaGuys Launch Ph...
  WiCON Officially Publishes Chi...
  WiCON Officially Publishes Its...
  WiCON Publishes China Pharmace...
© Wicon International Group  Support by: www.heightow.com Site map | Contact Us | Links